cancer cachexia
Conditions
Interventions
None listed
Sponsors
Hokkaido Gastrointestinal Cancer Study Group
Toyama University Hospital, Hirosaki University Hospital, Kushiro Rosai Hospital, Hakodate Municipal Hospital, Sapporo City General Hospital, Tonan Hospital, Hokkaido Medical Center, Wakkanai Municipal Hospital, Hakodate Central General Hospital, Sapporo Medical Center NTT EC, Miyazaki University Hospital, Iwamizawa Municipal General Hospital, Tomakomai City Hospital, Tokushukai Medical Corporation Sapporo Higashi Tokushukai Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Patients who were treated with anamorelin hydrochloride between April-November 2021. 2)Age <=20 years old at the time of initiation of anamorelin hydrochloride.
Exclusion criteria
Exclusion criteria: 1)Participation in the clinical trial is determined as unsuitable.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in FAACT appetite-related scores before and after starting anamorelin hydrochloride | — |
Secondary
| Measure | Time frame |
|---|---|
| 1)Change in body weight (kg) before and after starting anamorelin hydrochloride 2)Change in ECOG PS after anamorelin hydrochloride initiation 3)Frequency of anamorelin-related adverse events 4)Change in FAACT appetite-related score after anamorelin hydrochloride initiation by patient's background 5)Weight change after anamorelin hydrochloride initiation by patient's backgrounds 6)Change in ECOG PS after starting anamorelin hydrochloride by patient's backgrounds 7)Frequency of adverse events attributable to anamorelin hydrochloride by patient's backgrounds | — |
Countries
Japan
Contacts
Public ContactKazuaki Harada
Hokkaido university hospital Department of Gastroenterology and Hepatology
Outcome results
None listed